A telehealth prescription is not the end of a care process. Someone must evaluate the patient, select a treatment, arrange any insurance authorization, dispense the medicine and respond when questions arise. Mochi Health advertises help across that journey, including video consultations, nutrition support and medication delivery or local pickup. For an adult considering the service, the useful question is not simply what it sells, but who handles each step and which responsibilities remain unclear before enrollment.
This review examines Mochi’s public documentation consulted October 19, 2026. The four consulted pages describe a genuine GLP-1 care offering, with branded and compounded options, but they do not establish every eligibility rule, pharmacy arrangement or final cost. They also distinguish Mochi Health Corp.’s administrative role from the independent practices providing medical services. Following those boundaries reveals both the appeal of a coordinated platform and the details a prospective patient should obtain before paying.
At a glance
- Who provides medical care
- Mochi says licensed physicians and clinicians affiliated with independently owned and operated professional practices provide medical services; Mochi Health Corp. supplies administrative and technology services.Sources: [5]
- Intake and consultation
- The advertised pathway starts with a health-history questionnaire and includes a live, 30-minute video visit with a doctor on the tirzepatide page.Sources: [4]
- Medication starting prices
- Compounded subcutaneous tirzepatide starts at $90 and compounded subcutaneous semaglutide at $60, each plus membership, with no supply period stated in those price blocks. Compounded oral semaglutide starts at $62 per month plus membership.
- Membership payment
- One offer collects $199 today for the first 12 months. The advertised $17 monthly equivalent is not a $17 monthly billing arrangement; medications and diagnostic services are excluded.Sources: [5]
Start with the organization behind the appointment
Mochi’s corporate disclosure creates an important distinction: the platform is not itself the medical practice. It says professional medical services come from licensed physicians and clinicians affiliated with independently owned and operated practices. Mochi Health Corp. provides administrative and technology services to those practices. That arrangement is more specific than a general promise of online care, but the consulted pages do not identify the particular practice that would treat a given patient.
The homepage invites patients to choose a medical provider it describes as board certified and a registered dietitian. Those are provider statements, not credentials independently verified for this review. A clinician is not necessarily a physician, although the tirzepatide page specifically advertises a visit with a doctor. Before booking, ask for the treating professional’s name, credential and practice, and clarify which organization handles clinical records and questions about treatment decisions.
This division need not prevent coordinated care, but it makes the handoffs worth understanding. Platform support may help with scheduling or authorization while a treating professional makes prescribing decisions. Our guide to the clinician and platform distinction explains why those roles should not be treated as interchangeable. Mochi’s documentation establishes the organizational boundary; it does not fully map how a patient escalates a concern across it.
What happens before a prescription
The advertised intake begins with a short questionnaire about health history. The tirzepatide page then describes a live, 30-minute video consultation with a doctor. Thirty minutes is the stated visit duration, not a promise that an appointment will be available within half an hour. The homepage also says laboratory testing may be ordered when needed to obtain a fuller picture of a patient’s health. It does not publish a fixed testing requirement or a complete laboratory price list.
These steps describe an evaluation rather than a guaranteed prescription. The compounded medication pages expressly place prescribing at the provider’s discretion, and the injectable pages require a written prescription from a licensed provider. The consulted material does not establish minimum age, complete BMI criteria, contraindications or other eligibility rules. Nor does it explain what happens financially if the consultation ends without a prescription. Those are important questions before a patient purchases access to the process.
Preparation should focus on giving the treating professional an accurate history rather than trying to qualify through a marketing checklist. NIDDK identifies current conditions, other medicines, family history, potential side effects and costs as relevant to medication selection. Our first-consultation preparation guide offers a framework for organizing that discussion. Mochi’s public pathway supports asking how prior records are submitted, whether testing must be completed before prescribing and who communicates the results.
Identify the exact product, not just the ingredient
Mochi’s catalog spans several products and routes. Its compounded offerings include once-weekly subcutaneous tirzepatide and semaglutide injections. A separate page advertises a compounded, once-weekly oral semaglutide pill, prescribed at the provider’s discretion. The homepage also presents compounded, once-daily oral orforglipron and describes it as having no food or water restrictions. These are descriptions of the advertised offerings, not instructions to take a medicine or evidence that different formulations are interchangeable.
The branded catalog includes Zepbound and Wegovy injections, which the site describes in relation to chronic weight management and additional product-specific indications. It also lists Mounjaro for improving blood sugar control in adults with type 2 diabetes and Ozempic for type 2 diabetes with additional benefits in eligible adults. Those diabetes descriptions should not be silently rewritten as weight-loss approvals. The site additionally presents Foundayo as oral orforglipron, Wegovy Pill as oral semaglutide and metformin as an oral diabetes medicine.
Product-approval claims here belong to Mochi’s catalog, not an independent verification of each listing. FDA approval applies to a specific product, not to Mochi or an entire ingredient category. FDA also explains that compounded preparations are not FDA approved or subject to its premarket review for safety, effectiveness and quality. Nonapproval alone does not establish clinical inequivalence. FDA recommends compounded drugs when an individual’s medical needs cannot be met by an approved drug, with a prescription and a state-licensed pharmacy.
Separate access fees from the medicine bill
The clearest membership offer shows $199 due today for the first 12 months, alongside an advertised $17 monthly equivalent and a claimed $39 saving. That is upfront collection for that offer, not monthly collection of $17. A separate banner advertises $79 off membership and the first month free specifically on the one-month plan. It does not advertise free medication, and the consulted material does not establish that these two promotions can be combined.
Medication charges are separate. The $90 starting price for compounded injectable tirzepatide and $60 starting price for compounded injectable semaglutide do not specify a supply period in their quoted blocks. Both pages say price varies with the prescribed dose. Compounded oral semaglutide starts at $62 per month plus membership. These distinctions prevent a reliable all-in monthly comparison: the evidence supports the advertised figures, but not an assumed supply quantity or a guaranteed total.
Mochi explicitly excludes medications and diagnostic services from membership. Its insured-care block also says visits are billed through insurance, with the copay shown before commitment. That needs reconciliation with the separate promise of unlimited membership visits; unlimited access should not be read as a universal zero-copay guarantee. Before enrolling, request a breakdown identifying the selected membership, visit billing, prescribed product, laboratory charges and the amount payable if insurance does not cover a component.
| Offering | Advertised charge | Important condition |
|---|---|---|
| First 12 months of membership | $199 due today; advertised $17/month equivalent | Medication and diagnostic services excluded; later renewal charge not established |
| One-month membership promotion | $79 off; first month free | Specific to the one-month plan; not free medication |
| Compounded subcutaneous tirzepatide | Starting at $90 plus membership | Dose-dependent price; supply period not stated in the cited block |
| Compounded subcutaneous semaglutide | Starting at $60 plus membership | Dose-dependent price; supply period not stated in the cited block |
| Compounded oral semaglutide pill | Starting at $62/month plus membership | Advertised as once weekly; prescribing remains discretionary |
Insurance support does not settle coverage
If medication is prescribed, Mochi says it will handle prior authorization and arrange delivery or local pickup. It also advertises cash-pay and compounded options for people without insurance. Those are meaningful service commitments because the path from a clinical decision to a filled prescription can involve administrative work. They do not establish that an insurer will approve a requested medicine, that every product follows the same route or that a self-pay alternative will have the same final cost.
NIDDK notes that some insurance plans cover weight-management medicines and others do not. Coverage for a consultation must therefore be checked separately from coverage for a prescription. Mochi’s promise to show a visit copay before commitment helps with one part of the bill, but the consulted pages do not resolve all plan arrangements. Ask which visits will generate claims, what authorization support includes and how the team communicates a denial or request for additional information.
Geography is another explicit boundary: Mochi says medication availability and pricing vary by state. A geographic selector is not proof that every advertised treatment is offered everywhere. Before making a payment, confirm the exact product and care arrangement available where you live. The documentation does not establish universal clinical coverage, identify every state-specific pharmacy arrangement or confirm Spanish-language care, interpretation or clinical documents.
The pharmacy and delivery handoff needs more detail
Mochi says patients can purchase medications through its pharmacy network and advertises reliable shipping. The medication pages describe prescription fulfillment and delivery to the patient’s door; the homepage also mentions local pickup. However, the consulted material does not name the dispensing pharmacy or identify which pharmacy prepares a particular compounded product. Dispensing and compounding are different functions, and a promise of fulfillment does not tell a patient which organization performs each one.
The pages also do not establish clinical-review turnaround, appointment availability, dispatch timing, transit time or arrival guarantees. A 30-minute appointment and 24/7 support do not fill those gaps. Before the prescription moves forward, request the pharmacy’s name, contact route, expected processing sequence and the procedure for a delayed or damaged shipment. Our pharmacy handoff guide explains the questions that distinguish a platform’s coordination role from the pharmacy’s dispensing responsibilities.
Storage questions are especially important for injectable deliveries because the reviewed documentation does not specify cold-chain or replacement terms. FDA explicitly advises patients not to use an injectable GLP-1 drug that arrives warm or with insufficient refrigeration, and to contact the provider or dispensing pharmacy. That is a practical safety boundary, not evidence that Mochi shipments have such a problem. Patients should obtain the responsible contact before delivery rather than assume general support handles replacement decisions.
Follow-up is a service promise, not a response-time guarantee
Mochi advertises unlimited visits with the care team as part of membership. The homepage describes video visits as often as needed, ongoing nutrition and wellness guidance and follow-up laboratory testing. Together with access to a registered dietitian, that is a broader advertised offering than prescription fulfillment alone. Nevertheless, diagnostic services remain excluded from membership, and the pages do not specify a standard follow-up schedule, appointment capacity or the cost of each potential laboratory order.
The company also advertises 24/7 care-team support, including insurance and prior-authorization assistance. Availability is not the same as an immediate clinical response, and the documentation does not identify a response-time standard or explain which requests reach the prescriber. A prospective patient should ask how to request another video visit, who answers medication questions, how laboratory results are reviewed and what contact instructions apply when a concern cannot wait for routine messaging.
NIDDK frames follow-up around treatment response and tolerability, not simply continued payments. FDA has also reported measurement or administration errors involving compounded medicines, some associated with hospitalization; patients should clarify instructions with their prescriber or pharmacist rather than calculate doses from a review. Our guide to ongoing GLP-1 support helps translate a broad support promise into operational questions. Mochi’s compensated member testimonials do not independently establish how consistently those services perform.
Clarify the exit before starting the care relationship
The membership offer advertises personalized treatment options, no hidden fees and cancellation at any time. Those statements do not explain the financial result of canceling a prepaid 12-month offer. The consulted documentation does not establish a cancellation procedure, renewal deadline, subsequent charge or treatment of unused prepaid balances. Although a refund-policy link appears, the policy itself was not part of the consulted documentation. Cancellation must not be interpreted as a promise of a refund.
A useful pre-enrollment request would ask Mochi to identify the selected plan’s first charge, renewal amount and timing, cancellation steps and refund boundaries in writing. It should also ask what happens if no medication is prescribed or the requested product is unavailable in the patient’s state. These are distinct situations, and the public pages do not settle their payment consequences. The phrase “no hidden fees” cannot replace a specific explanation of excluded medication and diagnostic costs.
Continuity deserves the same attention as payment. Ask who remains responsible for pending laboratory results, an authorization still under review or a prescription already sent to a pharmacy when membership ends. The documentation does not establish those transition arrangements. NIDDK notes that treatment duration depends on response and side effects and that obesity may require long-term care. Ending a subscription is therefore an administrative decision that should not be confused with an individualized plan for changing treatment.
Questions & answers
Does Mochi Health Corp. directly provide the medical care?
Not according to its corporate disclosure. Mochi Health Corp. provides administrative and technology services, while independently owned and operated professional practices provide medical services through affiliated licensed physicians and clinicians. Ask which practice and professional will treat you, rather than assuming the platform name identifies the medical practice responsible for your care.
Does the advertised $17 per month include medication?
No. That figure is an advertised monthly equivalent attached to $199 collected today for the first 12 months. Mochi expressly excludes medications and diagnostic services from membership. It is not a documented $17 monthly payment plan, and the consulted pages do not establish the subsequent renewal charge or whether unused prepaid membership money is refundable.
Can I treat the $60 and $90 injectable prices as monthly totals?
No. Compounded subcutaneous semaglutide starts at $60 and compounded subcutaneous tirzepatide at $90, each plus membership. Their cited price blocks do not state a supply period, and both say price varies with the prescribed dose. The separate compounded oral semaglutide offer does state a starting price of $62 per month plus membership.
Will Mochi handle insurance authorization and pharmacy delivery?
Mochi says it handles prior authorization when medication is prescribed and coordinates delivery or local pickup. It also advertises a pharmacy network. Those statements do not guarantee insurance approval or a delivery date. The consulted material does not identify the pharmacy assigned to a particular patient, so confirm that handoff and its contact details before fulfillment.
Do unlimited visits and 24/7 support mean every contact is free and immediate?
The documentation does not establish that. Mochi advertises unlimited membership visits and around-the-clock support, but its insured-care block also describes visits billed through insurance with a disclosed copay. It publishes no response-time guarantee in these pages. Ask how your particular plan bills visits and which support channel reaches the treating professional.
What should I clarify before paying for Mochi?
Confirm the available treatment in your state, the treating practice, pharmacy identity, complete first charge and expected laboratory costs. Also request renewal, cancellation and refund terms, including what happens if no prescription is issued. Mochi documents state-based medication differences and separate medication and diagnostic charges, but the consulted pages do not resolve those other practical and financial boundaries.
Our assessment
Mochi documents a potentially useful coordinated pathway: health-history intake, a live consultation, discretionary prescribing, authorization assistance, pharmacy access and ongoing nutrition and clinical support. Its separation of the platform from independent medical practices is also meaningful disclosure. For someone evaluating care delivery, the strongest feature is the breadth of the advertised service rather than any demonstrated advantage in outcomes or speed. The remaining questions are operational and consequential: who treats and dispenses, how quickly each handoff occurs, what visits and tests cost, and what cancellation means for prepaid money. The published starting prices should remain visible, but they are not complete treatment totals. Mochi is therefore best understood as a documented telehealth weight-management offering whose patient-specific care and payment arrangements still require confirmation. Obtaining those details in writing is a more useful next step than relying on a promotional monthly equivalent, a support-availability claim or compensated testimonials.
This opens the reviewed business’s website. The link is not a prescription or endorsement. Commercial relationships.
Sources & documentation
Public materials consulted October 19, 2026. Provider statements are attributed claims, not independently verified clinical outcomes. Terms can change; obtain a current written quote.
- FDA concerns with unapproved GLP-1 drugs used for weight loss ↗
- NIDDK: prescription medications for overweight and obesity ↗
- Mochi Health — medications/compounded semaglutide ↗
- Mochi Health — medications/compounded tirzepatide ↗
- Mochi Health — official website ↗
- Mochi Health — medications/compounded semaglutide pill ↗